pharma · Amyotrophic Lateral Sclerosis (ALS) · COYA
Coya Therapeutics
Coave Therapeutics is a pharma organization headquartered in Paris, FR. It trades on NYSE under ticker COYA. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis (ALS). NovaPharmaNews links 1 clinical pr
Paris, FR HQ
2014 Founded
50 Employees
Public company Type
COYA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Paris, FR
- Founded
- 2014
- Employees
- 50
- Programs
- 1
- Drugs
- 0
- Patents
- 0
COYA 302
Phase 2 · small molecule · Amyotrophic Lateral Sclerosis (ALS)
COYA 302 for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (small_molecule) at Coya Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code C302-CLN-2301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Coya Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Amyotrophic Lateral Sclerosis (ALS)
- Status
- active
- Trials
- 1